Amalia
Pérez Gil
Publicacións nas que colabora con Amalia Pérez Gil (6)
2022
-
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study
F1000Research, Vol. 11
-
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
Dermatologic Therapy, Vol. 35, Núm. 10
-
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab
Dermatologic Therapy, Vol. 35, Núm. 11
-
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Life, Vol. 12, Núm. 11
-
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series
International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033
2020
-
Guselkumab: Short-term effectiveness and safety in real clinical practice
Dermatologic Therapy